Non-small cell lung cancer patient curative effect and prognosis prediction system

Abstract

The invention provides a non-small cell lung cancer patient curative effect and prognosis prediction system which comprises three prediction models of patient curative effect, progression-free survival and total survival. Each model comprises an input module, a calculation module and an output module. The input module transmits patient information to the calculation module, the input module of thecurative effect prediction model comprises a smoking history and an absolute lymphocyte count, the progression-free survival prediction model comprises age, gender and lactic dehydrogenase, the totalsurvival prediction model comprises lactic dehydrogenase and a derived neutrophile granulocyte ratio, a corresponding nomogram is arranged in the calculation module and used for calculating the effective probability of the patient in the sixth week, the probability of no progress in the sixth month, the twelfth month and the eighteenth month and the survival probability, and the output module isa web version calculator and can output a corresponding probability value. The system has the advantages of excellent prediction capability, good stability and efficiency, simple and rapid prediction,and very wide application prospect.

Description

technical field [0001] The invention belongs to the field of medicine and relates to a curative effect and prognosis prediction system for patients with non-small cell lung cancer. Background technique [0002] Lung cancer is the most common malignant tumor in my country and even in the world. Its morbidity and mortality rank first among malignant tumors. In recent years, the incidence and mortality of lung cancer have been on the rise. Among them, non-small cell lung cancer (NSCLC) accounts for 80% of the total number of lung cancers. %~85%. [0003] Currently, surgery, radiotherapy and chemotherapy, targeted therapy, and immunotherapy are the main treatments for NSCLC. Among them, immunotherapy targeting the immune checkpoint PD-1 / PD-L1 is a revolution in the treatment of advanced lung cancer in recent years, increasing the 5-year survival rate of advanced lung cancer from less than 5% to 26%. First-line and second-line treatment options for cell lung cancer. However, no...

AI Technical Summary

Problems solved by technology

[0005] Previous studies have found that markers such as PD-L1 expression, tumor mutational burden (TMB) and microsatellite instability (MSI) can predict the efficacy of immunotherapy, but the above tests need to be based on lung cancer tissue samples, which are difficult to obtain and repeated tests. Therefore, screening meaningful markers in patients' clinical characteristics and laboratory tests and establishing corresponding prediction models will help to easily and quickly predict the efficacy and prognosis of immunotherapy in patients with non-small cell lung cancer.

Images